Cleveland Clinic Florida's Cancer Research staff is dedicated to providing patients innovative therapies through clinical research trials which include new targeted agents and therapies. Cancer specialists from The Maroone Cancer's Departments of Hematology and Oncology serve as principal investigators for the trials, working closely with the research staff and collaborating with the world-renowned Taussig Cancer Institute at Cleveland Clinic in Ohio. Cleveland Clinic Florida also participates in many clinical trials with the National Cancer Institute.

For more information about our clinical trials, please contact:
Abel Rodriguez, Clinical Research Supervisor
Phone: 954.487.2258
Email: RODRIGA2@ccf.org

Areas of Cancer Clinical Trials

Brain Cancer

A Randomized Phase III Trial Of Memantine And Whole-Brain Radiotherapy With Or Without Hippocampal Avoidance In Patients With Brain Metastases


Breast Cancer

A Phase IB/II Dose-Escalation Study Evaluating The Combination Of Trastuzumab Emtansine (T-Dm1) With Neratinib In Women With Metastatic HER2-Positive Breast Cancer

A Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating The Use Of Adjuvant Endocrine Therapy +/- One Year Of Everolimus In Patients With High-Risk, Hormone Receptor-Positive And Her2/Neu Negative Breast Cancer

A Randomized Phase III Trial Of Endocrine Therapy Plus Entinostat/Placebo In Patients With Hormone Receptor-Positive Advanced Breast Cancer

NRG-BR003 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

A Phase III Study Evaluating Palbociclib (Pd-0332991), a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor in Patients With Hormone-Receptor- Positive, Her2-Normal Primary Breast Cancer With High Relapse Risk After Neoadjuvant Chemotherapy

Molecular Mechanisms Involved in Cancer Predisposition

  • Cleveland Clinic Study Number: IRB 8458
  • Principal Investigator: Charis Eng, MD

Gastrointestinal

SWOG S1505 - A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma


Genitourinary

A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer


Head & Neck Cancer

Please check back for upcoming trials.


Hematology

Please check back for upcoming trials.


Lung Cancer

A Study Of Nivolumab In Combination With Ipilimumab (Part 1); And Nivolumab Plus Ipilimumab In Combination With Chemotherapy vs. Chemotherapy Alone (*Part 2) As First Line Therapy In Stage Iv Non-Small Cell Lung Cancer
*Part 2 available at Cleveland Clinic Florida

Adjuvant Lung Cancer Enrichment Market Identification and Sequencing Trial (ALCHEMIST): A screening trial for A081105 and E4512

Randomized Double Blind Placebo Controlled Study of ERLOTINIB or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

A Phase III Double-Blind Trial for Surgically Resected Early State Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

A Randomized Phase III Study Of Nivolumab After Surgical Resection And Adjuvant Chemotherapy In Non-Small Cell Lung Cancers - Adjuvant Nivolumab In Resected Lung Cancers (Anvil)


Prostate Cancer

Androgen Deprivation Therapy And High Dose Radiotherapy With Or Without Whole-Pelvic Radiotherapy In Unfavorable Intermediate Or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial


Skin Cancer

A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma


Solid Tumor Cancer

An Open-Label, Multicenter, Global Phase II Basket Study Of Entrectinib For The Treatment Of Patients With Locally Advanced Or Metastatic Solid Tumors That Harbor Ntrk1/2/3, Ros1, Or ALK Gene Rearrangements

A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors